Kite And Juno Threatened By Cellectis' Off-The-Shelf CAR-T Success
This article was originally published in Start Up
An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite Pharma and Juno Therapeutics may become commercially obsolete before they even reach the market.
You may also be interested in...
Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.
Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.
Clinical trials for therapeutic areas aside from COVID-19 are experiencing disruptions and delays as social distancing measures and travel restrictions are implemented across the world.